ARCHIVES

Phase III Kyprolis Trial Fails OS Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 37 No. 8 | August 29, 2014

Download PDF Visit The Full Archive

Related Articles

FDA Approves Taxotere And Gemzar; Sends Approvable Letter For Etopophos

May 24, 1996

ACS Prostate Cancer Recommendations Move Forward

August 7, 1992

Groups Urge Congress To Enact NIH Budget Increase; Encourage Individual Letters

November 3, 1995

Cancer Control Planning Completed, Going Through Final Review Process

July 12, 1974

NIH Emerges From Republican Revolution With Another Increase in Appropriations

October 4, 1996

Ramucirumab Improves Overall Survival, Progression-Free Survival in Phase III Trial

October 26, 2012